Relationship between biomarkers and platelet aggregation activity in presence of hydrogen sulfide in patients with coronary heart disease
- Authors: Trubacheva O.A.1, Gusakova A.M.2, Schneider O.L.2, Birulina Y.G.1, Chumakova S.P.1, Petrova I.V.1
-
Affiliations:
- Siberian State Medical University
- National Research Medical Centre, Russian Academy of Sciences Research Institute of Cardiology
- Issue: Vol 27, No 1 (2024)
- Pages: 101-108
- Section: SHORT COMMUNICATIONS
- URL: https://journals.rcsi.science/1028-7221/article/view/263671
- DOI: https://doi.org/10.46235/1028-7221-16577-RBB
- ID: 263671
Cite item
Full Text
Abstract
Biological significance of hydrogen sulfide (H2S) in regulation of platelet functions and in development of thrombosis is being studied, but there is no consensus on the role of H2S in these physiological processes. The platelets are very sensitive to various mediators released from blood vessels and blood cells. Multiple pro-inflammatory molecules may exert direct effects on the state of cardiovascular system. Thus, an imbalance in the production of pro-inflammatory and anti-inflammatory cytokines increases the risk of thrombosis, and it can lead to endothelial dysfunction, instability and rupture of atherosclerotic plaques. The aim of our study was to determine concentrations and identify the relationships between certain biomarkers (LIGHT, PlGF, IFNá2, TNFáâ, IL-3, IL-5, IL-6, IL-8, IL-15, IL-17F, MIP-1á, CXCL16) and collagen-induced platelet aggregation in presence of hydrogen sulfide exposure in patients with coronary heart disease. We performed a simple one-step comparative study which included 22 patients with coronary artery disease (CHD). The level of biomarkers was determined by multiplex analysis (xMAP technology). Platelet aggregation activity was studied by the turbidimetric assay. All samples were examined against the background of a 30-min pre-incubation with hydrogen sulfide, with the addition of an aggregation inducer (collagen, 2 mmol/L). Sodium hydrosulfide at a concentration of 10-6 M was used as a hydrogen sulfide donor. The results of comparative and correlation analysis were considered reliable at a statistical significance level of p < 0.05. The patients were divided into two groups, i.e., group 1 (n = 10) showed a reduced aggregation or a decreased size of aggregates against the background of preincubation with H2S. In group 2 (n = 12), preincubation with H2S was followed by increased degree or size of platelet aggregates. The concentrations of tumor necrosis factor ligand (LIGHT), interferon IFNá2, interleukins IL-3, IL-8, IL-15, IL-17F, chemokine CCL3/MIP-1a were significantly increased in group 2 patients, where collagen-induced platelet aggregation increased upon preincubation H2S, as compared with patients in group 1. The correlation analysis revealed positive correlations found that in the 1st group of patients between the concentrations of MIP-1a (Rs = 0.56, p = 0.03; Rs = 0.69, p = 0.01), IL-5 (Rs = 0.83, p = 0.01; Rs = 0.73, p = 0.01), and IL-8 (Rs = 0.60, p = 0.02; Rs = 0.95, p = 0.01), respectively, and with both size of aggregates and the index of the platelet aggregation degree. Moreover, distinct correlations between the aggregate size and the concentration of IL-6 (Rs = 0.53, p = 0.04) were revealed. In the 2nd group of patients, correlations were found with the size of aggregates and PIGF (Rs = 0.59, p = 0.04), and between CXCL16 values and the size of aggregates (Rs = 0.58, p = 0.04), like as with the degree of aggregation (Rs = 0.65, p = 0.04). Thus, we have found that, in 2 groups of patients with coronary heart disease with increased collagen-induced platelet aggregation, preincubated with H2S, higher concentrations of inflammatory biomarkers (IFNá2, IL-3, IL-8, IL-15, IL-17F, MIP-1á) were detected. One may suggest that the more pronounced proinflammatory state in this group of patients may cause platelet resistance to inhibitory effect of hydrogen sulfide. In the 1st group of patients, we revealed multiple correlations of aggregation parameters with values of inflammatory markers (IL-5, IL-6, IL-8, MIP- 1a), which may be a pre-requisite for different corrective therapies for the patients of these groups.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Oksana A. Trubacheva
Siberian State Medical University
Author for correspondence.
Email: otrubacheva@inbox.ru
ORCID iD: 0000-0002-1253-3352
PhD (Medicine), Associate Professor, Department of Physical Culture and Health
Russian Federation, 634050, 2 Moskovsky tract TomskA. M. Gusakova
National Research Medical Centre, Russian Academy of Sciences Research Institute of Cardiology
Email: otrubacheva@inbox.ru
ORCID iD: 0000-0002-3147-3025
PhD (Pharmacy), Senior Research Associate, Department of Clinical Laboratory Diagnostics, Research Institute of Cardiology
Russian Federation, TomskO. L. Schneider
National Research Medical Centre, Russian Academy of Sciences Research Institute of Cardiology
Email: otrubacheva@inbox.ru
ORCID iD: 0000-0003-2461-1423
Junior Research Associate, Department of Atherosclerosis and Chronic Ischemic Heart Disease
Russian Federation, TomskYu. G. Birulina
Siberian State Medical University
Email: otrubacheva@inbox.ru
ORCID iD: 0000-0003-1237-9786
PhD (Biology), Associate Professor, Department of Biophysics and Functional Diagnostics
Russian Federation, 634050, 2 Moskovsky tract TomskS. P. Chumakova
Siberian State Medical University
Email: otrubacheva@inbox.ru
ORCID iD: 0000-0003-3468-6154
PhD, MD (Medicine), Professor, Department of Pathophysiology
Russian Federation, 634050, 2 Moskovsky tract TomskI. V. Petrova
Siberian State Medical University
Email: otrubacheva@inbox.ru
ORCID iD: 0000-0001-9034-4226
PhD, MD (Biology), Professor, Department of Biophysics and Functional Diagnostics
Russian Federation, 634050, 2 Moskovsky tract TomskReferences
- Козлов В.А. Определяющая роль тимуса в иммунопатогенезе аутоиммунных, онкологических и инфекционных заболеваний // Медицинская иммунология, 2023. Т. 25, № 1. С. 39-58. [Kozlov V.A. Determining role of thymus in immune pathogenesis of autoimmune, oncological and infectious diseases. Meditsinskaya immunologiya = Medical Immunology (Russia), 2023, Vol. 25, no. 1, pp. 39-58. (In Russ.)] doi: 10.15789/1563-0625-DRO-2591.
- Bando S., Fukuda D., Soeki T., Nishimoto S., Uematsu E., Matsuura T., Ise T., Tobiume T., Yamaguchi K., Yagi S., Iwase T., Yamada H., Wakatsuki T., Shimabukuro M., Sata M. Expression of NLRP3 in subcutaneous adipose tissue is associated with coronary atherosclerosis. Atherosclerosis, 2015, Vol. 242, no. 2, pp. 407-414.
- Cipolletta D., Cohen P., Spiegelman B.M., Benoist C., Mathis D. Appearance and disappearance of the mRNA signature characteristic of Treg cells in visceral adipose tissue: age, diet, and PPARγ effects. Proc. Natl Acad. Sci. USA, 2015, Vol. 112, no. 2, pp. 482-487.
- Dai X., Zhang D., Wang C., Wu Z., Liang C. The pivotal role of thymus in atherosclerosis mediated by immune and inflammatory response. Int. J. Med. Sci., 2018, Vol. 15, no. 13, pp. 1555-1563.
- Ferreira R.C., Simons H.Z., Thompson W.S., Rainbow D.B., Yang X., Cutler A.J., Oliveira J., Castro Dopico X., Smyth D.J., Savinykh N., Mashar M., Vyse T.J., Dunger D.B., Baxendale H., Chandra A., Wallace C., Todd J.A., Wicker L.S., Pekalski M.L. Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity. J. Autoimmun., 2017, Vol. 84, pp. 75-86.
- Gadekar T., Dudeja P., Basu I., Vashisht S., Mukherji S. Correlation of visceral body fat with waist-hip ratio, waist circumference and body mass index in healthy adults: A cross sectional study. Med. J. Armed Forces India, 2020, Vol. 76, no. 1, pp. 41-46.
- Gao Z., Xu X., Li Y., Sun K., Yang M., Zhang Q., Wang S., Lin Y., Lou L., Wu A., Liu W., Nie B. Mechanistic Insight into PPARγ and Tregs in Atherosclerotic Immune Inflammation. Front. Pharmacol., 2021, Vol. 12, 750078. doi: 10.3389/fphar.2021.750078.
- Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am. J. Cardiol., 1983, Vol. 51, no. 3, 606. doi: 10.1016/s0002-9149(83)80105-2.
- Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat. Rev. Cardiol., 2022, Vol. 19, pp. 593-606.
- Ni X., Kou W., Gu J., Wei P., Wu X., Peng H., Tao J., Yan W., Yang X., Lebid A., Park B.V., Chen Z., Tian Y., Fu J., Newman S., Wang X., Shen H., Li B., Blazar B.R., Wang X., Barbi J., Pan F., Lu L. TRAF6 directs FOXP3 localization and facilitates regulatory T-cell function through K63-linked ubiquitination. EMBO J., 2019, Vol. 38, no. 9, e99766. doi: 10.15252/embj.201899766.
- Sima P., Vannucci L., Vetvicka V. Atherosclerosis as autoimmune disease. Ann. Transl. Med., 2018, Vol. 6, no. 7, 116. doi: 10.21037/atm.2018.02.02
- Wang Q., Wu H. T cells in adipose tissue: critical players in immunometabolism. Front. Immunol., 2018, Vol. 9, 2509. doi: 10.3389/fimmu.2018.02509.
- Yang H., Youm Y.H., Dixit V.D. Inhibition of thymic adipogenesis by caloric restriction is coupled with reduction in age-related thymic involution. J. Immunol., 2009, Vol. 183, no. 5, pp. 3040-3052.
- Yu Y., Bai H., Wu F., Chen J., Li B., Li Y. Tissue adaptation of regulatory T cells in adipose tissue. Eur. J. Immunol., 2022, Vol. 52, no. 12, pp. 1898-1908.
- Zeng Q., Sun X., Xiao L., Xie Z., Bettini M., Deng T. A unique population: adipose-resident regulatory T cells. Front. Immunol., 2018, Vol. 9, 2075. doi: 10.3389/fimmu.2018.02075.